Show simple item record

dc.contributor.authorFonagy, Peter
dc.contributor.authorYakeley, Jessica
dc.contributor.authorGardner, Tessa
dc.contributor.authorSimes, Elizabeth
dc.contributor.authorMcMurran, Mary
dc.contributor.authorMoran, Paul
dc.contributor.authorCrawford, Mike
dc.contributor.authorFrater, Alison
dc.contributor.authorBarrett, Barbara
dc.contributor.authorCameron, Angus
dc.contributor.authorWason, James
dc.contributor.authorPilling, Stephen
dc.contributor.authorButler, Stephen
dc.contributor.authorBateman, Anthony
dc.date.accessioned2020-12-07T16:15:37Z
dc.date.available2020-12-07T16:15:37Z
dc.date.issued2020-12-07
dc.date.submitted2020-07-17
dc.identifier.others13063-020-04896-w
dc.identifier.other4896
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/314818
dc.description.abstractAbstract: Background: Antisocial personality disorder (ASPD), although associated with very significant health and social burden, is an under-researched mental disorder for which clinically effective and cost-effective treatment methods are urgently needed. No intervention has been established for prevention or as the treatment of choice for this disorder. Mentalization-based treatment (MBT) is a psychotherapeutic treatment that has shown some promising preliminary results for reducing personality disorder symptomatology by specifically targeting the ability to recognize and understand the mental states of oneself and others, an ability that is compromised in people with ASPD. This paper describes the protocol of a multi-site RCT designed to test the effectiveness and cost-effectiveness of MBT for reducing aggression and alleviating the wider symptoms of ASPD in male offenders subject to probation supervision who fulfil diagnostic criteria for ASPD. Methods: Three hundred and two participants recruited from a pool of offenders subject to statutory supervision by the National Probation Service at 13 sites across the UK will be randomized on a 1:1 basis to 12 months of probation plus MBT or standard probation as usual, with follow-up to 24 months post-randomization. The primary outcome is frequency of aggressive antisocial behaviour as assessed by the Overt Aggression Scale – Modified. Secondary outcomes include violence, offending rates, alcohol use, drug use, mental health status, quality of life, and total service use costs. Data will be gathered from police and criminal justice databases, NHS record linkage, and interviews and self-report measures administered to participants. Primary analysis will be on an intent-to-treat basis; per-protocol analysis will be undertaken as secondary analysis. The primary outcome will be analysed using hierarchical mixed-effects linear regression. Secondary outcomes will be analysed using mixed-effects linear regression, mixed-effects logistic regression, and mixed-effects Poisson models for secondary outcomes depending on whether the outcome is continuous, binary, or count data. A cost-effectiveness and cost-utility analysis will be undertaken. Discussion: This definitive, national, multi-site trial is of sufficient size to evaluate MBT to inform policymakers, service commissioners, clinicians, and service users about its potential to treat offenders with ASPD and the likely impact on the population at risk. Trial registration: ISRCTN 32309003. Registered on 8 April 2016.
dc.languageen
dc.publisherBioMed Central
dc.rightsAttribution 4.0 International (CC BY 4.0)en
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en
dc.subjectStudy Protocol
dc.subjectAntisocial personality disorder
dc.subjectRandomized controlled trial
dc.subjectMentalization-based treatment
dc.subjectProbation
dc.subjectPersonality disorder
dc.subjectOffenders
dc.subjectAggression
dc.subjectViolence
dc.subjectPatient and public involvement
dc.subjectEconomic evaluation
dc.titleMentalization for Offending Adult Males (MOAM): study protocol for a randomized controlled trial to evaluate mentalization-based treatment for antisocial personality disorder in male offenders on community probation
dc.typeArticle
dc.date.updated2020-12-07T16:15:36Z
prism.issueIdentifier1
prism.publicationNameTrials
prism.volume21
dc.identifier.doi10.17863/CAM.61923
dcterms.dateAccepted2020-11-12
rioxxterms.versionofrecord10.1186/s13063-020-04896-w
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/
dc.contributor.orcidFonagy, Peter [0000-0003-0229-0091]
dc.identifier.eissn1745-6215
pubs.funder-project-idNational Institute for Health Research (14/186/01)


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International (CC BY 4.0)
Except where otherwise noted, this item's licence is described as Attribution 4.0 International (CC BY 4.0)